Skip to main content
. 2015 Mar 14;21(10):3100–3108. doi: 10.3748/wjg.v21.i10.3100

Table 2.

Patient characteristics of included studies

Ref. Groups n Age (yr) Sex (M/F) Etiology (alcohol/viral/other) Child-Pugh score or class A/B/C Follow-up (mo) Lost to follow-up Small varices, n No varices, n
Andreani et al[11] Propranolol 43 55.0 ± 1.3 27/16 33/-/10 10/19/13 NA 6 15 0
Placebo 41 55.6 ± 1.7 23/18 33/-/8 10/21/10 NA 2 17 0
Conn et al[16] Propranolol 51 54 ± 9 38/13 39/-/12 Mean: 8.0 17.1 ± 10.9 NA 26 0
Placebo 51 54 ± 11 35/16 41/-/10 Mean: 8.3 16.3 ± 12 NA 29 0
Calés et al[12] Propranolol 102 52.7 ± 10.4 69/33 88/-/24 6.8 ± 2.1 NA 41 60 42
Placebo 104 52.7 ± 11.4 68/36 81/-/23 6.8 ± 2.0 NA 32 67 37
Merkel et al[14] Nadolol 83 56 ± 9 45/38 47/34/2 6.8 ± 1.6 36 ± 18 11 83 0
Placebo 78 57 ± 9 38/40 45/28/5 7.1 ± 1.9 35 ± 15 10 78 0
Groszmann et al[13] Timolol 108 46 ± 11 70/38 26/73/9 5.4 ± 0.7 Median: 52.7 0 0 108
Placebo 105 44 ± 11 56/49 25/69/11 5.4 ± 0.8 Median: 57.9 0 0 105
Sarin et al[15] Propranolol 77 42 ± 13 63/14 27/42/8 7.4 ± 1.9 25 ± 12.6 0 77 0
Placebo 73 44 ± 13 57/16 26/38/9 7.7 ± 2.3 0 73 0

F: Female; M: Male; NA: Not available. Note: data are expressed as mean ± SD unless otherwise indicated.